Bristol-Myers Squibb Newsroom

Bristol-Myers Squibb To Go Ex-Dividend On January 3rd, 2025 With 0.62 USD Dividend Per Share

December 11th (Eastern Time) - $Bristol-Myers Squibb(BMY.US)$ is trading ex-dividend on January 3rd, 2025.Shareholders of record on January 3rd, 2025 will receive 0.62 USD dividend per share on

Futu News08:40

Bristol-Myers Squibb Boosts Quarterly Dividend $0.02 to $0.62 a Share, Payable Feb. 3 to Investors of Record Jan. 3

MT Newswires05:25

Press Release: Bristol Myers Squibb Announces Dividend Increase

Dow Jones05:17

Bristol Myers Squibb Announces Dividend Increase >BMY

Dow Jones05:17

Berenberg Bank Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $60

Futu NewsDec 11 15:33 · Ratings

Berenberg Bank Remains a Hold on Bristol-Myers Squibb (BMY)

TipRanksDec 11 14:35 · Ratings

BofA Restarts Coverage of 11 Large-cap Biopharmas

Seeking AlphaDec 11 06:01

Bristol Myers Stock Surges 36.5% in Six Months: Time to Buy or Sell?

Zacks Dec 11 01:30

B of A Securities Reinstates Neutral on Bristol-Myers Squibb, Announces $63 Price Target

BenzingaDec 10 20:40 · Ratings

Bristol-Myers Squibb Analyst Ratings

BenzingaDec 10 20:39 · Ratings

BMO Capital Downgrades Bristol-Myers Squibb(BMY.US) to Hold Rating, Maintains Target Price $61

Futu NewsDec 10 20:31 · Ratings

Bristol-Myers Squibb: Balancing Stability and Competition With Cautious Optimism

TipRanksDec 10 20:26

Express News | Bristol-Myers Squibb Co : Berenberg Raises Target Price to $60 From $55

BreakingsDec 10 14:11

Express News | Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at Ash 2024 With Long-Term Survival Data and Results From Expanding Pipeline

BreakingsDec 10 06:45

Jumo Health Is Fierce DEI Award Finalist for Remarkable Achievement, Positive Change in Healthcare

PR NewswireDec 7 03:22

Unusual Options Activity: MTDR, NEE and Others Attract Market Bets, MTDR V/OI Ratio Reaches 177.8

EST Dec 6th Afternoon Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options

Futu NewsDec 7 02:30

Kaposi Sarcoma Strategic Market Research Report 2024-2030, Competitor Profiles of 14 Players Including Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer - ResearchAndMarkets.com

BusinesswireDec 6 04:08

Express News | CFRA has downgraded bristol-myers squibb's rating to hold, with a target price of 60 dollars.

BreakingsDec 4 05:04

PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy

Zacks Dec 3 23:35

AI Proteins Announces Research Collaboration and Option Agreement With Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M

BusinesswireDec 3 21:00